Drug Database
OM

omeprazole

✓ Approved

Santarus, Inc. · ATP4A · Small Molecule

What is omeprazole?

omeprazole is a small molecule developed by Santarus, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanySantarus, Inc.
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Santarus, Inc.

Mechanism of Action

Molecular Targets

omeprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

omeprazole is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

Related Research Articles

PubMedMaterials (Basel, Switzerland)2026-10-16

Effect of Al Content on Synthesis, Mechanical Properties and Corrosion Resistance of Ti3(Si,Al)C2 MAX Solid Solutions.

Bao Mingdong M, Hu Jiahuan J, Cao Yingwen Y

MAX-phase solid solution has attracted much attention for research dealing with complex and harsh working conditions. Solid solutions in a Ti-Al-Si-C system were fabricated from Ti, Si, TiC and Al powders by hot press sintering at 1400 °C for 2 h. Phase identification and micro-morphology were systematically characterized, followed by nano-indentation for mechanical tests and electrochemical tests in NaOH for alkali corrosion tests. The c-lattice parameter increased linearly while the a-parameter was essentially unchanged, which followed Vegard's law and also suggested strong anisotropy of MAX-phase lattices. The addition of Al element caused a solid-solution-strengthening effect, increasing the nano-indentation and elastic modulus. In the electrochemical tests in NaOH solution, with the increased Al content, the corrosion tendency gradually decreased with the increasing charge transfer obstruction, which suggested improved corrosion resistance.

PMID 42882558
Read full article →
PubMedInfection control and hospital epidemiology2026-10-16

Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening for MRSA in a clinical culture in solid organ transplant recipients.

Schultheis Jennifer J, Hanlon Ellen E, Deri Connor C, Bergin Stephen P SP et al.

In this retrospective cohort study of 318 solid organ transplant (SOT) recipients, the MRSA nasal PCR demonstrated high specificity (0.95) and negative predictive value (0.98) for MRSA in clinical cultures. In low-risk SOT recipients, negative MRSA nasal PCR may support de-escalation of therapy; exploratory results require confirmation in higher-prevalence cohorts.

PMID 42885188
Read full article →
PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

Thoracic Pathologies Requiring Surgical or Interventional Management in Solid-Organ Transplant Recipients.

Yucemen Ayse Ugurum AU, Issi Sinan S, Safak Adem A, Karakaya Emre E et al.

Thoracic pathologies are important causes of morbidity in solid-organ transplant recipients because of chronic immunosuppression, transplant-related complications, and diverse underlying etiologies. We aimed to evaluate thoracic pathologies requiring surgical or interventional management after solid-organ transplantation, present our clinical outcomes, and propose an anatomical management framework for these complex conditions. We conducted a retrospective cohort study at a tertiary referral center of solid-organ transplant recipients who underwent surgical or interventional treatment for thoracic pathologies between 2010 and 2025. Patients who were managed conservatively or patients who had incomplete clinical data were excluded. Demographic characteristics, transplant-related variables, thoracic pathology type, surgical or interventional procedures, histopathological findings, postoperative complications, and clinical outcomes were analyzed descriptively. Twenty-one transplant recipients underwent 28 thoracic interventions during the study period. The cohort included 12 liver, 8 kidney, and 1 heart transplant recipient, with a mean age of 42.0 ± 22.2 years; 66.7% were male. Thoracic pathologies involved pleural, parenchymal, and mediastinal compartments and required individualized management using tube thoracostomy, video-assisted thoracoscopic surgery, thoracotomy, or mediastinoscopy. Histopathological evaluation demonstrated a broad spectrum of infectious, inflammatory, and malignant diseases, including aspergilloma, tuberculosis, primary lung carcinoma, hepatocellular carcinoma metastasis, inflammatory pseudotumor, and polymorphic post-transplant lymphoproliferative disease. Postoperative complications occurred in 2 patients (9.5% ). One patient required 2 subsequent thoracotomies for prolonged air leak caused by a parenchymal fistula and postoperative hemothorax, whereas another underwent rethoracotomy for recurrent hemorrhage after initial surgical treatment of hemothorax. Thoracic pathologies following solid-organ transplant comprise a heterogeneous group of conditions requiring individualized multidisciplinary management. Surgical and interventional procedures play a pivotal role in both establishing definitive diagnoses and providing effective treatment. Early recognition, careful patient selection, and pathology-specific management strategies may improve clinical outcomes in this complex and high-risk population.

PMID 42885708
Read full article →
PubMedPolymers2026-10-16

Graphene-Confined Silicon and a Li6.5La3Zr1.5Ta0.5O12-Reinforced Plasticized Poly(ethylene oxide) Electrolyte Enable Contact-Stable Solid-State Lithium Batteries.

Liu Xianzheng X, Jamadon Nashrah Hani NH, Li Jiayi J, Liu Xiaoxi X et al.

Silicon is a promising anode for solid-state lithium batteries because of its high theoretical capacity, but large lithiation-induced volume changes and unstable electrode/electrolyte contact remain major challenges. Here, a contact-adaptive solid-state silicon (Si) architecture is developed by coupling an electrostatically assembled silicon/reduced graphene oxide (Si@rGO) nanosheet anode with a poly(ethylene oxide) (PEO)-lithium bis(trifluoromethanesulfonyl)imide (LiTFSI)-ethylene carbonate (EC) electrolyte reinforced with 10 wt% Ta-doped Li6.5La3Zr1.5Ta0.5O12 (LLZTO), hereafter denoted PEC-T. Trace EC promotes Li-salt solvation and PEO plasticization, while LLZTO suppresses polymer crystallization and reinforces ion transport. PEC-T shows a reduced melting temperature from 66.7 to 51.4 °C, improved tensile strength and elongation, an ionic conductivity of 3.0 × 10-4 S cm-1 at 30 °C, a Li+ transference number of 0.57, and an oxidative stability limit of ~4.5 V. It also supports stable Li plating/stripping for 600 h at 0.1 mA cm-2. Meanwhile, the rGO framework mitigates irreversible Si thickness evolution and preserves interfacial integrity. Consequently, Si@rGO/PEC-T/Li batteries deliver strong rate capability and maintain 1.8 Ah g-1 after 250 cycles at 1 C, demonstrating a coupled chemo-mechanical strategy for stable solid-state silicon batteries.

PMID 42885005
Read full article →
PubMedJournal of clinical medicine2026-10-16

Clozapine and Solid Cancer Risk in Lithuania: A Population-Based Cohort Study.

Drevinskaite Mingaile M, Germanavicius Arunas A, Smailyte Giedre G

Background: People with schizophrenia may experience altered cancer risk because of lifestyle-, healthcare access-, and treatment-related factors. Evidence on the solid cancer risk associated with clozapine remains limited. We aimed to assess solid cancer incidence among clozapine users in Lithuania between 2013 and 2021. Methods: We conducted a retrospective population-based cohort study linking National Health Insurance Fund records with the Lithuanian Cancer Registry. Patients with schizophrenia treated with clozapine during 2013-2021 were followed from the first recorded clozapine prescription until death, emigration, or 31 December 2021. Standardized incidence ratios (SIR) for cancers were calculated as the ratio of observed cancer cases in the clozapine user cohort to the expected number of cancers in the general Lithuanian population. Results: The cohort included 3473 clozapine users and 91 incident cancers. Overall cancer incidence was lower than expected in males. Among men with at least 3 years of clozapine exposure, prostate cancer incidence was reduced (SIR 0.47, 95% CI 0.22-0.98). Among women with at least 3 years of exposure, corpus uteri cancer incidence was increased (SIR 2.42, 95% CI 1.21-4.83). Conclusions: Current evidence on solid cancer incidence among clozapine users remains limited. Prolonged exposure may be associated with cancer-specific rather than uniform changes in risk. These exploratory findings should be interpreted cautiously and support continued attention to cancer surveillance and further large-scale pharmacoepidemiological studies with longer follow-up.

PMID 42882198
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Enhanced Dissolution and Oral Bioavailability of Tegoprazan Using D-α-Tocopheryl Polyethylene Glycol 1000 Succinate-Based Melt Granulation System.

Jeong Min Gyeong MG, Kim Tae Hyoung TH, Yang In Gyu IG, Baek Yeon Ju YJ et al.

Tegoprazan (TPZ) is a promising potassium-competitive acid blocker, but its pH-dependent low solubility often leads to erratic oral absorption. Although several hydrophilic polymer-based amorphous solid dispersions have been attempted to enhance dissolution, they often suffer from thermodynamic instability or rely on complex, solvent-mediated manufacturing processes. Herein, to enhance dissolution and oral absorption, a crystalline drug-loaded melt granulation (MG) system using D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was fabricated while maintaining stable physicochemical properties. MGs were prepared via a solvent-free, hot-melt process by optimizing the type of solid surfactant carrier, the ratio of drug to solid surfactant, and the type and ratio of flow-enhancing excipients. The optimized composition was TPZ:TPGS:microcrystalline cellulose = 1:2:4 (w/w/w). Solid-state analyses revealed that TPZ was uniformly dispersed within the granules while retaining its crystalline form. Compared to the raw drug, the MG showed remarkably faster and higher dissolution across both acidic and neutral media. Under long-term (25 °C/60% RH) and accelerated storage conditions (40 °C/75% RH) for 24 weeks, MG exhibited robust physicochemical stability, showing no drug degradation, changes in dissolution behavior, or crystalline alterations. Moreover, in a pharmacokinetic evaluation in Sprague-Dawley rats, MG provided marked absorption enhancement, yielding over 1.8-fold increases in exposure compared to the raw material. Consequently, the crystalline drug-loaded TPGS-based MG represents a promising strategy for improving the oral delivery of TPZ.

PMID 42883150
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about omeprazole